erythroblastosis fetalis

(redirected from Hemolytic disease of the newborn)
Also found in: Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.

erythroblastosis fe·ta·lis

A severe hemolytic disease of a fetus or newborn infant caused by the production of maternal antibodies against the fetal red blood cells, usually involving Rh incompatibility between the mother and fetus. Also called RH disease.

[New Latin erythroblastōsis fētālis : erythroblastōsis, erythroblastosis + fētālis, fetal.]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.erythroblastosis fetalis - severe anemia in newborn babies; the result of Rh incompatibility between maternal and fetal blood; typically occurs when the child of an Rh-negative mother inherits Rh-positive blood from the father; can be diagnosed before birth by amniocentesis
anemia, anaemia - a deficiency of red blood cells
References in periodicals archive ?
FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn.
Takeda Pharmaceutical Company announced that the United States Food and Drug Administration has approved the company's second submission for its new plasma manufacturing facility near Covington, Georgia for the production of FLEXBUMIN 25% USP, 25% Solution, indicated for hypovolemia, hypoalbuminemia, cardiopulmonary bypass surgery, and hemolytic disease of the newborn. Albumin is not indicated as an intravenous nutrient.
Hemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2007;92(2):F83-8.
Hemolytic disease of the newborn occurs as a result of hemolysis and shortening of the life span of the new-born's erythrocytes because of antibodies crossing from the mother by the placenta (5).
Hemolytic disease of the fetus and newborn (originally termed hemolytic disease of the newborn) was first clinically described by Levine et al.
Hemolytic disease of the newborn is characterized by immune mediated hemolysis of the neonatal red cells by the maternal antibodies via transplacental route.
and Walker, W.: Controlled trials of the treatment of Hemolytic disease of the newborn. The Lancet 1952; 429-433.
The jaundice was felt to be due to ABO hemolytic disease of the newborn (mother O negative, newborn B negative, direct antiglobulin test positive) and was treated successfully by a 36-h regimen of phototherapy.
(1) In the 13 years since that survey was conducted, case reports of Rhpositive persons forming anti-D have continued to accumulate, (17-25) including at least 1 additional case of fatal Rh hemolytic disease of the newborn. (26) Also, there has been considerable progress in elucidating the molecular basis of the weak D phenotype.

Full browser ?